SCAI Cardiogenic Shock Classification Tool
Clinical Staging Assessment
Select the current clinical findings and support requirements. Assess the patient at the time of evaluation.
The SCAI SHOCK classification is a clinical severity framework, not a mortality calculator or treatment protocol.
Reassess the stage as the clinical condition and response to therapy evolve.
About the SCAI SHOCK Classification
The Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK classification provides a standardized framework for describing the severity of cardiogenic shock in adults. The stages range from patients at risk (Stage A) to those with extremis and actual or impending circulatory collapse (Stage E).
The 2022 expert consensus update incorporates validation studies and refines the clinical, biochemical, and hemodynamic descriptors. It emphasizes dynamic reassessment and the distinction between shock severity and overall mortality risk.
Stage descriptors
| Stage | Descriptor | Core clinical concept |
|---|---|---|
| A | At risk | At risk for cardiogenic shock, without current signs or symptoms of shock. |
| B | Beginning | Hemodynamic instability without hypoperfusion (pre-shock). |
| C | Classic | Hypoperfusion requiring an intervention beyond volume resuscitation. |
| D | Deteriorating | Failure of initial support to restore perfusion; worsening or escalating support. |
| E | Extremis | Actual or impending circulatory collapse, often with ongoing resuscitation. |
Important clinical considerations
- Stage B is distinguished from Stage C by the presence of hypoperfusion; hypotension alone does not establish classic cardiogenic shock.
- Stage C generally requires hypoperfusion and at least one pharmacological or mechanical intervention beyond volume resuscitation.
- Stage D requires failure of an initial support strategy. An element of time and reassessment is necessary; worsening despite therapy is central to this stage.
- Stage E may result from catastrophic deterioration from any lower stage.
- The lactate threshold of ≥2 mmol/L supports recognition of hypoperfusion but must be interpreted in context; normal lactate does not exclude hypoperfusion.
- Invasive hemodynamics, when available, and bedside examination should be integrated rather than treated as isolated mandatory checkboxes.
References
DOI: 10.1016/j.jscai.2021.100008
DOI: 10.1002/ccd.28329
DOI: 10.1016/j.jacc.2019.07.077
Official PDF resource
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.